Medicare Enrolled
Dr. Sanjay Vadgama, M.D.
Pulmonary Disease · Sherman Oaks, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Vadgama from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Vadgama?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Vadgama
Dr. Sanjay Vadgama is a pulmonary disease specialist in Sherman Oaks, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Vadgama performed 3,685 Medicare services across 1,044 unique beneficiaries.
Between the years covered by Open Payments, Dr. Vadgama received a total of $7,450 from 57 pharmaceutical and/or device companies across 329 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Vadgama is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 8% volume in CA
$7,450 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,685
Medicare services
Top 8% in CA for pulmonary disease
1,044
Unique beneficiaries
$96
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~184 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
2,491 | $66 | $167 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
713 | $177 | $500 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
255 | $146 | $500 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
120 | $109 | $246 |
| Initial nursing facility care, moderate complexity Initial care provided to a patient in a nursing facility with moderate medical decision making, taking at least 35 minutes. |
32 | $113 | $289 |
| Nursing facility visit, low complexity A daily follow-up visit for an existing patient in a nursing facility involving straightforward medical decision making. The visit requires at least 15 minutes of time if time is used to determine the level of care. |
32 | $63 | $154 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
18 | $135 | $376 |
| Insertion of non-tunneled central venous catheter A procedure to place a central venous catheter for infusion in patients aged 5 years or older. The catheter is inserted directly into a large vein without being tunneled under the skin. |
12 | $69 | $300 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
12 | $100 | $239 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.3% high complexity
0.0% medium
99.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$7,450
Total received (2018-2024)
Avg $1,064/year across 7 years
Top 21% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
57
Companies
329
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,265 (97.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$185 (2.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,777
2023
$1,210
2022
$928
2021
$810
2020
$724
2019
$867
2018
$1,134
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$236
Philips North America LLC
$228
United Therapeutics Corporation
$209
Insmed, Inc.
$154
AngioDynamics, Inc.
$146
AstraZeneca Pharmaceuticals LP
$124
Pulmonx Corporation
$101
Amgen Inc.
$100
GlaxoSmithKline, LLC.
$80
Mylan Specialty L.P.
$76
Boehringer Ingelheim Pharmaceuticals, Inc.
$67
Novartis Pharmaceuticals Corporation
$56
Ceribell, Inc.
$40
Grifols USA, LLC
$26
Regeneron Healthcare Solutions, Inc.
$24
Optinose US, Inc.
$24
Electromed, Inc.
$23
Vifor Pharma, Inc.
$22
Mallinckrodt Hospital Products Inc.
$21
PFIZER INC.
$18
Top 3 companies account for 37.9% of 2024 payments
All-time payments by company (2018-2024) ›
Boehringer Ingelheim Pharmaceuticals, Inc.
$644
GlaxoSmithKline, LLC.
$543
AstraZeneca Pharmaceuticals LP
$410
United Therapeutics Corporation
$377
Philips Electronics North America Corporation
$350
Grifols USA, LLC
$335
PFIZER INC.
$319
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$314
Amgen Inc.
$306
Pulmonx Corporation
$245
Mallinckrodt Hospital Products Inc.
$239
Philips North America LLC
$228
Mylan Specialty L.P.
$225
E.R. Squibb & Sons, L.L.C.
$189
BAXTER HEALTHCARE
$185
Insmed, Inc.
$181
Actelion Pharmaceuticals US, Inc.
$154
Allergan Inc.
$146
AngioDynamics, Inc.
$146
Electromed, Inc.
$127
AbbVie Inc.
$125
Harmony Biosciences LLC
$118
Mallinckrodt Enterprises LLC
$115
Sunovion Pharmaceuticals Inc.
$109
Janssen Pharmaceuticals, Inc
$98
Merck Sharp & Dohme Corporation
$93
Genentech USA, Inc.
$78
Gilead Sciences, Inc.
$76
Regeneron Healthcare Solutions, Inc.
$73
Paratek Pharmaceuticals, Inc.
$63
Allergan, Inc.
$59
Novartis Pharmaceuticals Corporation
$56
La Jolla Pharmaceutical Company
$56
ADVANCED RESPIRATORY, INC
$54
CMP Pharma, Inc.
$52
Advanced Respiratory, Inc
$49
Merck Sharp & Dohme LLC
$45
HARMONY BIOSCIENCES LLC
$44
ABBVIE INC.
$42
Ceribell, Inc.
$40
Takeda Pharmaceuticals U.S.A., Inc.
$31
Melinta Therapeutics, LLC
$29
Baxter Healthcare
$26
Optinose US, Inc.
$24
ABIOMED
$24
Alexion Pharmaceuticals, Inc.
$23
Bayer HealthCare Pharmaceuticals Inc.
$22
Vifor Pharma, Inc.
$22
Itamar Medical Inc
$21
JAZZ PHARMACEUTICALS INC.
$20
Vapotherm Inc
$17
Circassia Pharmaceuticals Inc
$16
ACADIA Pharmaceuticals Inc
$15
Ventec Life Systems, Inc.
$14
Sanofi Pasteur Inc.
$14
Sun Pharmaceutical Industries Inc.
$13
Mallinckrodt LLC
$11
Top 3 companies account for 21.4% of all-time payments
Associated products mentioned in payments ›
(4570) DreamStation Cpap Core Cell · (7999) SRC Und · (8874) inCourage · ACTHAR · AIRSUPRA · ANDEXXA · AREXVY · AURYON LASER SYSTEM 100-120 VAC · AVYCAZ · Adempas · Arikayce · BREZTRI · BROVANA · CHARTIS CATHETER · Carospir · DALVANCE · DIFICID · DUPIXENT · ELIQUIS · ENTRESTO · Esbriet · FASENRA · FLUZONE HIGH-DOSE · GIAPREZA · GLASSIA · Hillrom - Life 2000 Ventilation System · Impella · KAPSPARGO · LOKELMA · LONHALA MAGNAIR · Life 2000 Ventilation System · LifeVest · NUPLAZID · NUZYRA · No Related Product · OFEV · OPSUMIT · POCKET EEG DEVICE · Precision Flow · Prolastin-C Liquid · Repatha · Respiratoriy Care Undiv · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · Soliris · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Monarch Airway Clearance System · The Vest System Model 105 Home Care · Trilogy 100 · UPTRAVI · Utibron · VYNDAQEL · Vabomere · Veklury · Wakix · WatchPAT · Wellcentive Undiv · XARELTO · XERAVA · Xhance · Xolair · YUPELRI · Yupelri · ZERBAXA · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
230
Per 100K population
2.3
County median income
$87,760
Nearest hospital
SHERMAN OAKS HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Vadgama is a mixed practice specialist, with above-average Medicare volume (top 8% in CA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Vadgama experienced with hospital follow-up visit, moderate complexity?
Based on Medicare claims data, Dr. Vadgama performed 2,491 hospital follow-up visit, moderate complexity services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Vadgama receive payments from pharmaceutical companies?
Yes. Dr. Vadgama received a total of $7,450 from 57 companies across 329 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Vadgama's costs compare to other pulmonary diseases in Sherman Oaks?
Dr. Vadgama's average Medicare payment per service is $96. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Vadgama) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Sherman Oaks
Browse pulmonary diseases in Sherman Oaks ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology